StreetAlpha.app
Home › Stocks › CING

Cingulate Inc. (CING)

Healthcare
$4.72
▲ +25.87%
LAST CLOSE · NOV 17

Cingulate develops once-a-day ADHD and anxiety medicines using its proprietary drug delivery platform. It last closed at $4.72 on Nov 17, up 25.87% on the day. The average 12-month price target from 2 analysts is $26.50 (+461.4% from the last close), with a high of $44.00 and a low of $9.00.

AI Auto Pilots
Is CING in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$29.2M
EPS (diluted)
−$2.67
Free cash flow
−$24.2M
Valuation
Market cap
$70.6M
15.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.2M
At Sep 30
Shareholder equity
$20.8M
Shares outstanding
15.0M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $99K$99KFY2024FY2025: −$1.4M−$1.4MFY2025

From CING's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CING in the past 90 days, not enough for a consensus
Average 12-month target
$26.50
▲ 461.4% upside

Based on 2 analysts who set a price target on CING in the past 90 days. The average target is $26.50, with a high of $44.00 and a low of $9.00, compared with the last close of $4.72.

Low $9.00Avg $26.50High $44.00
Blue marker: last close $4.72
Highest target$44.00
Average target$26.50
Lowest target$9.00
Latest rating changes
Roth CapitalReiterated
Aug 24Buy$9
Ascendiant CapitalTarget lowered
Aug 20Buy$52 → $44
Ascendiant CapitalMaintained
Jun 8Buy$52
HC Wainwright & Co.Reiterated
May 26Buy$20
DateFirmActionRatingPrice target
Aug 24Roth CapitalReiteratedBuy$9
Aug 20Ascendiant CapitalTarget loweredBuy$52 → $44
Jun 8Ascendiant CapitalMaintainedBuy$52
May 26HC Wainwright & Co.ReiteratedBuy$20
Loading…

Technical Analysis

CING · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 14% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 51). The nearest support is the 20 day average at $4.71, and the nearest resistance the 50 day average at $4.82.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 8.3%/day
Key levels
$11.8952 week high+151.9%
$5.37200 day average+13.8%
$5.08Pivot R1+7.6%
$4.94100 day average+4.7%
$4.84Swing high (Nov 10)+2.5%
$4.8250 day average+2.1%
$4.72Last close
$4.7120 day average−0.2%
$4.71Swing low (Aug 14)−0.2%
$4.57Pivot−3.2%
$4.21Pivot S1−10.8%
$3.1652 week low−33.1%
Indicators
RSI (14)51.32Middle of its rangeNeutral
MACD-0.14Below its signal lineBearish
Stochastic26.9Middle of its rangeNeutral
ADX (14)17.3No clear trend
Williams %R-32.8Oversold below −80, overbought above −20Neutral
CCI (20)-30.8Oversold below −100, overbought above 100Neutral
Rate of change+0.0%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 8.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for CING

What happened before

See how CING did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CING usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CING has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CING in the last 90 days.

Loading…

See today’s whale options flow across the market →

CING Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲29 buying vs 9 selling
  • ▲Held by funds +5.9 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4134+20.6%
In funds' top 1000–
Held by funds19.1%13.2%+5.9 pts
New / increased14 / 1510 / 16+11.5%
Reduced / sold out3 / 64 / 4+12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CING institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CING is in one of them and how their past CING trades turned out.

CING in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CING in an article yet. Here's the latest on the wider market.

About Cingulate

Cingulate is a biopharmaceutical company based in Kansas City, Kansas. It uses its proprietary Precision Timed Release drug delivery platform to develop medicines that release doses at set times, so patients can take them one time a day. Its lead candidate, CTx-1301, is a stimulant for attention deficit hyperactivity disorder and is under review by the U.S. Food and Drug Administration. The company is also developing a buspirone tablet for anxiety, with patients, physicians and payers as its intended users.

Headquarters
Kansas City, KS